Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III study of PTI-428, PTI-808 and PTI-801 combination

Trial Profile

A Phase III study of PTI-428, PTI-808 and PTI-801 combination

Phase of Trial: Phase III

Latest Information Update: 20 Dec 2018

At a glance

  • Drugs PTI 428 (Primary) ; PTI 808 (Primary) ; PTI NC 733 (Primary) ; PTI-801 Proteostasis Therapeutics (Primary)
  • Indications Cystic fibrosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Proteostasis Therapeutics
  • Most Recent Events

    • 20 Dec 2018 According to a Proteostasis Therapeutics media release, assuming positive results from doublet and triplet studies, the company expect to be in a position to initiate Phase 3 studies within the next 12-18 months.
    • 30 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top